SAN FRANCISCO, Nov. 6 – Nanogen completed internal validation of a DNA-based  research protocol for the MTHFR mutation to use on the NanoChip Molecular Biology Workstation, the company announced Tuesday.

MTHFR is associated with cardiovascular disease and the pathology of thrombosis. Protocol users will have the option to further develop and validate the protocols for internal use, the company said.

This is the fourth DNA-based research protocol that the San Diego-based company has internally validated for use on the NanoChip Molecular Biology Workstation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.